A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF.
Alvarez RD, et al. Among authors: lobuglio af.
Clin Cancer Res. 2002 Sep;8(9):2806-11.
Clin Cancer Res. 2002.
PMID: 12231520
Clinical Trial.